Proteomic analysis of HBV-associated HCC: Insights on mechanisms of disease onset and biomarker discovery

Journal of Proteomics

Volumn 73, Issue 7, 2010, Pages 1283-1290

  Niu, Dandan ^a   Feng, Huixing ^a   Chen, Wei Ning ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

HBX; Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); Prognostic biomarkers

Indexed keywords

ALPHA FETOPROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN M; CALCIUM BINDING PROTEIN; CARCINOEMBRYONIC ANTIGEN; CELL PROTEIN; CYTOSKELETON PROTEIN; DNA; HEAT SHOCK PROTEIN 27; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR MARKER; UVOMORULIN;

CANCER DIAGNOSIS; CELL ADHESION; CELL MOTILITY; DISEASE ASSOCIATION; DNA METHYLATION; GENE EXPRESSION SYSTEM; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; RADIOFREQUENCY ABLATION; REVIEW; TWO DIMENSIONAL ELECTROPHORESIS;

CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, COMPUTER-ASSISTED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

HEPATITIS B VIRUS;

EID: 77950918155     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.02.016     Document Type: Review

References (69)

1. Avila M.A., and Lu K.P. Hepatitis B virus x protein and pin1 in liver cancer: "les liaisons dangereuses". Gastroenterology 132 (2007) 1180-1183
2. Liu J., Lian Z., Han S., Waye M.M., Wang H., Wu M.C., et al. Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene 25 (2006) 1008-1017
3. Lee S.W., Lee Y.M., Bae S.K., Murakami S., Yun Y., and Kim K.W. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun 268 (2000) 456-461
4. Sun W., Zhong F., Zhi L., Zhou G., and He F. Systematic -omics analysis of HBV-associated liver diseases. Cancer Lett 286 1 (2009) 89-95
5. Bantscheff M., Schirle M., Sweetman G., Rick J., and Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 389 (2007) 1017-1031
6. Pei Y., Zhang T., Renault V., and Zhang X. An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin (Shanghai) 41 (2009) 1-15
7. Liang C.R., Leow C.K., Neo J.C., Tan G.S., Lo S.L., Lim J.W., et al. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 5 (2005) 2258-2271
8. Sun W., Xing B., Sun Y., Du X., Lu M., Hao C., et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics 6 (2007) 1798-1808
9. Li C., Hong Y., Tan Y.X., Zhou H., Ai J.H., Li S.J., et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics 3 (2004) 399-409
10. Lee N.P., Chen L., Lin M.C., Tsang F.H., Yeung C., Poon R.T., et al. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res 8 (2009) 1293-1303
11. Niu D., Sui J., Zhang J., Feng H., and Chen W.N. iTRAQ-coupled 2-D LC-MS/MS analysis of protein profile associated with HBV-modulated DNA methylation. Proteomics 9 (2009) 3856-3868
12. Zhang J., Niu D., Sui J., Ching C.B., and Chen W.N. Protein profile in hepatitis B virus replicating rat primary hepatocytes and HepG2 cells by iTRAQ-coupled 2-D LC-MS/MS analysis: insights on liver angiogenesis. Proteomics 9 (2009) 2836-2845
13. Kuramitsu Y., and Nakamura K. Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Expert Rev Proteomics 2 (2005) 589-601
14. Yoon S.K. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology 51 Suppl 1 (2008) 34-41
15. Li C., Tan Y.X., Zhou H., Ding S.J., Li S.J., Ma D.J., et al. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics 5 (2005) 1125-1139
16. Li N., Long Y., Fan X., Liu H., Li C., Chen L., et al. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res 28 (2009) 122
17. Kim W., Oe Lim S., Kim J.S., Ryu Y.H., Byeon J.Y., Kim H.J., et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res 9 (2003) 5493-5500
18. Paradis V., Degos F., Dargere D., Pham N., Belghiti J., Degott C., et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology (Baltimore, Md.) 41 (2005) 40-47
19. Poon T.C., Yip T.T., Chan A.T., Yip C., Yip V., Mok T.S., et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49 (2003) 752-760
20. Steel L.F., Shumpert D., Trotter M., Seeholzer S.H., Evans A.A., London W.T., et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3 (2003) 601-609
21. He Q.Y., Zhu R., Lei T., Ng M.Y., Luk J.M., Sham P., et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. J Cell Biochem 103 (2008) 740-752
22. Findeisen P., Zapatka M., Peccerella T., Matzk H., Neumaier M., Schadendorf D., et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 27 (2009) 2199-2208
23. Mao L., Dong H., Yang P., Zhou H., Huang X., Lin X., et al. MALDI-TOF/TOF-MS reveals elevated serum haptoglobin and amyloid A in Behcet's disease. J Proteome Res 7 (2008) 4500-4507
24. Bozinovski S., Hutchinson A., Thompson M., Macgregor L., Black J., Giannakis E., et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177 (2008) 269-278
25. Tan T.L., and Chen W.N. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: potential in identification of early diagnostic markers for HCC. J Clin Virol 33 (2005) 293-298
26. Tong A., Gou L., Lau Q.C., Chen B., Zhao X., Li J., et al. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J Proteome Res 8 (2009) 1037-1046
27. Qiu G.H., Salto-Tellez M., Ross J.A., Yeo W., Cui Y., Wheelhouse N., et al. The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J Hepatol 48 (2008) 433-441
28. Tong A., Wu L., Lin Q., Lau Q.C., Zhao X., Li J., et al. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 8 (2008) 2012-2023
29. Hu Z., Zhang Z., Kim J.W., Huang Y., and Liang T.J. Altered proteolysis and global gene expression in hepatitis B virus X transgenic mouse liver. J Virol 80 (2006) 1405-1413
30. Niu D., Sui J., Zhang J., Feng H., and Chen W.N. iTRAQ-coupled 2-D LC-MS/MS analysis of protein profile associated with HBV-modulated DNA methylation. Proteomics 9 (2009) 3856-3868
31. Narayan R., Gangadharan B., Hantz O., Antrobus R., Garcia A., Dwek R.A., et al. Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. J Proteome Res 8 (2009) 118-122
32. Li L., Chen S.H., Yu C.H., Li Y.M., and Wang S.Q. Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res 7 (2008) 611-620
33. Tan T.L., Feng Z., Lu Y.W., Chan V., and Chen W.N. Adhesion contact kinetics of HepG2 cells during hepatitis B virus replication: involvement of SH3-binding motif in HBX. Biochim Biophys Acta 1762 (2006) 755-766
34. Liu X., Wang L., Zhang S., Lin J., Zhang S., Feitelson M.A., et al. Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis 29 (2008) 1207-1214
35. Theamboonlers A., Jantaradsamee P., Kaew-In N., Tangkijvanich P., Hirsch P., and Poovorawan Y. The predominant genotypes of hepatitis B virus in Thailand. Ann Trop Med Parasitol 93 (1999) 737-743
36. Macdonald A., Crowder K., Street A., McCormick C., Saksela K., and Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem 278 (2003) 17775-17784
37. Chung T.W., Moon S.K., Lee Y.C., Kim J.G., Ko J.H., and Kim C.H. Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Arch Biochem Biophys 408 (2002) 147-154
38. Lara-Pezzi E., Majano P.L., Yanez-Mo M., Gomez-Gonzalo M., Carretero M., Moreno-Otero R., et al. Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. J Hepatol 34 (2001) 409-415
39. Bouchard M.J., Wang L.H., and Schneider R.J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science (New York, NY) 294 (2001) 2376-2378
40. Bouchard M.J., Puro R.J., Wang L., and Schneider R.J. Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 77 (2003) 7713-7719
41. McClain S.L., Clippinger A.J., Lizzano R., and Bouchard M.J. Hepatitis B virus replication is associated with an HBx-dependent mitochondrion-regulated increase in cytosolic calcium levels. J Virol 81 (2007) 12061-12065
42. Hu Z., Zhang Z., Doo E., Coux O., Goldberg A.L., and Liang T.J. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J Virol 73 (1999) 7231-7240
43. Kurebayashi J. Biomarkers in breast cancer. Gan To Kagaku Ryoho 31 (2004) 1021-1026
44. Piantino P., Arrigoni A., Brunetto M.R., and Gindro T. Alpha-fetoprotein in hepatic pathology and hepatocarcinoma. J Nucl Med Allied Sci 33 (1989) 34-38
45. Lok A.S., and Lai C.L. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 9 (1989) 110-115
46. Feng J.T., Liu Y.K., Song H.Y., Dai Z., Qin L.X., Almofti M.R., et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5 (2005) 4581-4588
47. Kawakami T., Hoshida Y., Kanai F., Tanaka Y., Tateishi K., Ikenoue T., et al. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 5 (2005) 4287-4295
48. Kalabay L., Jakab L., Prohaszka Z., Fust G., Benko Z., Telegdy L., et al. Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 14 (2002) 389-394
49. Kalabay L., Graf L., Voros K., Jakab L., Benko Z., Telegdy L., et al. Human serum fetuin A/alpha2HS-glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores. BMC Gastroenterol 7 (2007) 15
50. Yokoyama Y., Kuramitsu Y., Takashima M., Iizuka N., Terai S., Oka M., et al. Protein level of apolipoprotein E increased in human hepatocellular carcinoma. Int J Oncol 28 (2006) 625-631
51. Henry L., Lavabre-Bertrand T., Vercambre L., Ramos J., Carillo S., Guiraud I., et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 58 (2009) 833-838
52. Su H., Zhao J., Xiong Y., Xu T., Zhou F., Yuan Y., et al. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China. Mutat Res 641 (2008) 27-35
53. Hellebrekers D.M., Melotte V., Vire E., Langenkamp E., Molema G., Fuks F., et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67 (2007) 4138-4148
54. Park I.Y., Sohn B.H., Yu E., Suh D.J., Chung Y.H., Lee J.H., et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132 (2007) 1476-1494
55. Oh B.K., Kim H., Park H.J., Shim Y.H., Choi J., Park C., et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med 20 (2007) 65-73
56. Jung J.K., Arora P., Pagano J.S., and Jang K.L. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res 67 (2007) 5771-5778
57. Zhang Y.J., Wu H.C., Shen J., Ahsan H., Tsai W.Y., Yang H.I., et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 13 (2007) 2378-2384
58. Zhu R., Li B.Z., Li H., Ling Y.Q., Hu X.Q., Zhai W.R., et al. Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis. Pathol Int 57 (2007) 328-336
59. Zhu Y.Z., Zhu R., Fan J., Pan Q., Li H., Chen Q., et al. Hepatitis B virus X protein induces hypermethylation of p16(INK4A) promoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis. J Viral Hepatitis 17 2 (2010) 98-107
60. Lee J.O., Kwun H.J., Jung J.K., Choi K.H., Min D.S., and Jang K.L. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 24 (2005) 6617-6625
61. Niu D., Zhang J., Ren Y., Feng H., and Chen W.N. HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Mol Oncol 3 (2009) 67-76
62. Zheng D.L., Zhang L., Cheng N., Xu X., Deng Q., Teng X.M., et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 50 (2009) 377-387
63. Ko E., Kim S.J., Joh J.W., Park C.K., Park J., and Kim D.H. CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett 271 (2008) 240-250
64. Tangkijvanich P., Hourpai N., Rattanatanyong P., Wisedopas N., Mahachai V., and Mutirangura A. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta Int J Clin Chem 379 (2007) 127-133
65. Chang H., Yi B., Li L., Zhang H.Y., Sun F., Dong S.Q., et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol 85 (2008) 96-100
66. Komatsu K., Kobune-Fujiwara Y., Andoh A., Ishiguro S., Hunai H., Suzuki N., et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 83 (2000) 769-774
67. Paweletz C.P., Ornstein D.K., Roth M.J., Bichsel V.E., Gillespie J.W., Calvert V.S., et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60 (2000) 6293-6297
68. Chetcuti A., Margan S.H., Russell P., Mann S., Millar D.S., Clark S.J., et al. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 61 (2001) 6331-6334
69. Sui J., Zhang J., Ching C.B., and Chen W.N. Comparative proteomic analysis of extracellular proteins reveals secretion of T-kininogen from vascular smooth muscle cells in response to incubation with s-enantiomer of propranolol. Mol Pharm 5 (2008) 885-890